Carestream Health and Bruker have entered into an agreement for Bruker
to purchase the preclinical in-vivo imaging equipment product portfolio
and related assets from Carestream's Molecular Imaging business.
Financial terms of the agreement are not being disclosed.
As part of the transaction, the majority of Carestream employees
involved in the preclinical in-vivo imaging business will be offered the
opportunity to join Bruker. It is anticipated that the transaction will
close in the next several weeks.
Carestream will retain the remaining assets of its Molecular Imaging
business, including its life science X-ray film product lines and its
Gel Logic and Image Station in-vitro imaging equipment product
portfolio. Carestream will continue operating its life science X-ray
film business, and will continue to support its in-vitro product
customers with service and parts. New production of its Gel Logic and
Image Station in-vitro products will be discontinued.
Dr. Werner Maas, President of Bruker BioSpin Corporation, commented: "We
are excited about adding Carestream's in-vivo imaging systems to our
preclinical imaging product portfolio. We believe that Carestream's
optical molecular imaging product line will complement our other
preclinical solutions, presently consisting of magnetic resonance
imaging (MRI), magnetic particle imaging (MPI) and X-ray micro computed
tomography (microCT). We also welcome the talented Carestream in-vivo
employees to Bruker, and look forward to their contributions."
Source: Bruker Corporation